Published on March 11, 2010 at 7:39 AM
Response Biomedical Corporation (TSX: RBM, OTCBB: RPBIF) reported that
it recorded total revenues of $9,946,269, an increase of 69% compared to
$5,876,337 in 2008. Clinical products revenue for the year ended
December 31, 2009 increased 85% to $6,828,651 compared to $3,683,706 in
2008.
“2009 was the strongest revenue year in the history of the Company and
we are poised to realize similar growth in 2010”
For the year ended December 31, 2009, the Company reported a net loss of
$9,543,531 or $0.04 per share compared to a loss of $13,663,656 or $0.10
per share in 2008. Additionally, the Company announced that as of
December 31, 2009, it had approximately $7 million in working capital.
For a further discussion of the Company’s financial results for the year
ended December 31, 2009, please refer to the Company’s audited
consolidated financial statements and related Management Discussion and
Analysis, which can be found at www.responsebio.com,
SEDAR (Canada) www.sedar.com
or EDGAR (US) www.sec.gov/edgar/searchedgar/webusers.htm.
Information at these sites is typically available within 24 hours of the
distribution of the news release.
“2009 was the strongest revenue year in the history of the Company and
we are poised to realize similar growth in 2010,” said S. Wayne Kay,
Chief Executive officer. “Our success in 2009 was driven in great part
by our partners, Roche Diagnostics and 3M Health Care, as they continue
to recognize achievements in the U.S. O&D Biotech, our distribution
partner in China, was also a strong contributor to our overall growth in
clinical products revenue in 2009 and Shionogi continued to show steady
expansion in Japan.”
Source Response Biomedical